Insights into Generalized Anxiety Disorder - Market Insight, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

The "Generalized Anxiety Disorder (GAD) - Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the GAD, historical and forecasted epidemiology as well as the GAD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The GAD market report provides current treatment practices, emerging drugs, GAD market share of the individual therapies, current and forecasted GAD market size from 2017 to 2030 segmented by seven major markets. The Report also covers current GAD treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Generalized Anxiety Disorder Diagnosis

GAD is diagnosed when a person finds it difficult to control worry on more days than not for at least 6 months. An evaluation of symptom criteria, as outlined in DSM-5, is the first step for diagnosis followed by physical exam, blood tests, urine tests, gastric reflux tests, such as an X-ray of the digestive system or an endoscopy procedure to look at the esophagus, and stress tests.

Generalized Anxiety Disorder (GAD) Epidemiology

The GAD epidemiology division provides the insights about historical and current GAD patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted GAD epidemiology [segmented as Total12-Month Prevalent Cases of Generalized Anxiety Disorder in 7MM (Adult, Adolescents and Children),Gender-Specific Prevalence of Generalized Anxiety Disorder in 7MM, Age-Specific Prevalence of Generalized Anxiety Disorder, Severity-Specific Prevalence of Generalized Anxiety Disorder] scenario of GAD in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise-Generalized Anxiety Disorder Epidemiology

• The Total 12-Month Prevalent Cases of GAD in 7MM was 16,606,987 in 2017, based on DSM-V criteria. Estimates show that the United States accounted for the highest number of cases of GAD among all the 7MM countries, i.e., 11,113,727. Among the EU5, France has the highest prevalence with estimated 1,304,965 cases in 2017.
• In 2017, there were a total of 4,083,434 cases of GAD in the age-group (18-24), and 685,341 cases in 65 and above, in the United States.
• The severity of GAD Is divided into mild, moderate, or severe based on the number of criteria symptoms such as a functional disability in work role performance, household maintenance, social life, and intimate relationships with the severity of the symptoms.
• In 2017, there were 238,201 mild cases, 459,904 moderate cases and 333,070 severe cases of GAD in the US. The overall children and adolescent specific severity specific cases of GAD are subjected to increase in the coming years.

Report Highlights

• In the coming years, Generalized Anxiety Disorder market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Generalized Anxiety Disorder. Launch of emerging therapies, will significantly impact the Generalized Anxiety Disorder market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Generalized Anxiety Disorder.
• The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Generalized Anxiety Disorder market.
• To understand the future market competition in the Generalized Anxiety Disorder market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Generalized Anxiety Disorder in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Generalized Anxiety Disorder market.
• To understand the future market competition in the Generalized Anxiety Disorder market.

Companies Mentioned

• Bionomics
• Pherin Pharmaceuticals
• VistaGen Therapeutics
• BioHaven Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7ogczj

View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005695/en/